How hormones affect long‑acting cabotegravir for HIV prevention
Official title: CHIPP-PrEP: Cabotegravir- Hormone Interrogation of Pharmacokinetics-Pharmacodynamics for HIV Prevention
Funded at Johns Hopkins University · NIH-11159781 · Data updated 2026-11-12
This project looks at how natural and taken hormones change how the long‑acting HIV prevention injection cabotegravir behaves in the body for people at risk of HIV.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $601,598 |
| NIH project number | 5R01AI186440-02 |
| Project ID | NIH-11159781 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are people at risk of HIV who are using or considering long‑acting cabotegravir and people taking hormonal therapies (for contraception or gender‑affirming care).
✕Less likely to help
People not using cabotegravir for prevention or people with no exposure to hormonal treatments may not see direct benefit from this work.
What this research studies
From your perspective, the team wants to know whether hormones you make naturally or hormones you take (like birth control or gender‑affirming therapy) change how the long‑acting cabotegravir injection is absorbed, held in the body, and cleared. Researchers will analyze clinical trial data and biological samples, measuring hormone levels, body mass index, and injection site factors to see how these affect drug levels over time. They will use population pharmacokinetic modeling to predict cabotegravir concentrations in blood and in genital and rectal tissues across different people. The focus includes differences by sex and by use of exogenous hormones to better understand protection against HIV in real-world groups.
Why it matters
Potential benefit: If successful, this could support more personalized guidance or dosing so cabotegravir offers reliable protection for people on different hormone regimens and body types.
How similar studies have gone: Previous trials such as HPTN 077 found sex‑based differences in cabotegravir levels, but combining detailed hormone measurements with population PK modeling is a relatively new approach.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Marzinke, Mark a — Johns Hopkins University
- Study coordinator: Marzinke, Mark a
Related research
Other NIH-funded projects on the same topics.
-
CAB-LA and Hormones: How Biology Affects HIV Prevention Medicine
A Johns Hopkins study will look at how natural and added hormones might change how a long-acting HIV prevention drug works in the body.
-
Investigating the effects of hormone therapy on HIV prevention in transgender individuals
This study is looking at how estrogen hormone therapy affects the way the HIV prevention pill cabotegravir works in transgender women and gender diverse people, so we can make sure they can safely use this medication while on hormone therapy.
-
Harnessing male peer networks to boost HIV testing and PrEP use
A large clinical trial in South Africa tests whether giving HIV self-test kits through male peer networks, with phone support, increases PrEP uptake among men.
-
Harnessing men's peer networks to boost HIV self-testing and PrEP use
A large project in South Africa tests whether giving HIV self-test kits through men’s social networks, with phone support, can lead to more men starting PrEP and using HIV testing.
-
TB PrEP: Bringing HIV prevention to households affected by TB in Uganda
Aims to help people in households with TB in Uganda access HIV PrEP as part of a combined prevention approach.
-
How choosing PrEP products could improve HIV protection for young women in Kenya
This project looks at which HIV-prevention options young Kenyan women prefer and how choosing a product affects how well they stay protected.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.